2561 — Visen Pharmaceuticals Balance Sheet
0.000.00%
- HK$3.23bn
- HK$2.35bn
Annual balance sheet for Visen Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Short Term Investments | 626 | 348 | 204 |
| Net Total Receivables | 70.6 | 13.5 | 9.57 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 712 | 374 | 223 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 17.2 | 13.3 | 11.2 |
| Net Intangible Assets | |||
| Long Term Notes Receivable | |||
| Other Long Term Assets | |||
| Total Assets | 741 | 444 | 294 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 87.3 | 51.8 | 52.2 |
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Liabilities | 88.7 | 52.9 | 52.5 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Treasury Stock | |||
| Other Equity | |||
| Total Equity | 653 | 391 | 241 |
| Total Liabilities & Shareholders' Equity | 741 | 444 | 294 |
| Total Common Shares Outstanding |